Overview

A 12-Week Open-Label Study to Investigate the Efficacy and Safety of Brepocitinib in Adults With Skin-Predominant Dermatomyositis

Status:
COMPLETED
Trial end date:
2025-02-28
Target enrollment:
Participant gender:
Summary
This is a prospective, 12-week, open-label, single-arm study. The study population comprises individuals with refractory skin disease characteristic of dermatomyositis with no to minimal muscle involvement. After an up to 8-week Screening Period, eligible participants will receive brepocitinib 30 mg orally (PO) QD for 12 weeks.
Phase:
PHASE2
Details
Lead Sponsor:
Priovant Therapeutics, Inc.